G

BalançosGyre Therapeutics

GYRE

A Gyre Therapeutics Inc é uma empresa farmacêutica de estágio comercial que desenvolve e comercializa antiinflamatórios e antifibróticos de pequenas moléculas contra doenças orgânicas, com foco específico na fibrose orgânica. Os produtos comerciais da empresa incluem ETUARY, Avatrombopag e Nintedanib. Além disso, está focado no desenvolvimento e comercialização de Hidronidona (F351) para o tratamento da Esteatohepatite Associada à Disfunção Metabólica (fibrose MASH). A Gyre também está promovendo diversos candidatos a fármacos na China, incluindo F573, F528 e F230. Os segmentos reportáveis da empresa são a Gyre Pharmaceuticals, que obtém receita máxima da venda de ETUARY e de certos genéricos na RPC, Gyre e outros.

Tabela de balanços completa e atualizada com os principais indicadores financeiros: Lucro Líquido, Receita, EBTIDA, Margem, ROE, Dividendos

Ano
12/2015
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2016
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2017
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2018
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2019
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2020
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2021
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2022
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2023
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2024
106
18
01
11%
0.12
63
19%
-27
-
-4
-3
2
-8
0
0
-
-